Related Experiment Video
Updated: May 13, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy
Shuji Murakami1, Haruhiro Saito, Miki Ohe
1Department of Thoracic Oncology, Kanagawa Cancer Center Hospital, Japan. murakamis@kcch.jp
Abstract:
Drug-induced vessel vasculitis is a rare complication of chemotherapy. In particular, few reports have investigated drug-induced large vessel vasculitis. We herein report the case of a 57-year-old woman with advanced lung adenocarcinoma who developed perinuclear anti-neutrophil cytoplastic antibodies (p-ANCA)-positive periaortitis induced by bevacizumab combination chemotherapy. With the increasing use of combination therapy with bevacizumab, the incidence of vascular complications will potentially increase. A noninfectious fever occurring during chemotherapy might be a sign of vasculitis; therefore, we must ensure that possible periaortitis is not overlooked.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Cytotoxic Edema: Pathophysiology
Hypersensitivity Reactions: Immune-Complex Reactions
Tumor Immunotherapy
Hypersensitivity Reactions: Cytolytic Reactions